
Intensive lowering of low-density lipoprotein cholesterol (LDL-C) can produce partial regression of coronary plaque, according to randomized imaging trials published in JAMA and JAMA Cardiology. In a prespecified analysis of the 104-patient FLOWPROMOTE trial published on October 30, 2026, more intensive treatment reduced total coronary plaque volume by 21.1% over 18 months, compared with 13.6% with atorvastatin alone. These imaging findings do not establish that narrowed arteries fully reopen or that the measured plaque reduction necessarily prevents heart attacks.
Imaging trials show that coronary plaque can shrink without disappearing
Coronary atherosclerosis develops as cholesterol-rich particles enter the arterial wall and contribute to inflammation, lipid accumulation, scar-like tissue formation, and changes in the vessel’s structure. The process can begin long before symptoms appear, as illustrated by research on silent plaque in young adults. Lowering circulating LDL-C reduces one of the main drivers of plaque formation and can change existing lesions over time.
The strongest direct evidence for regression comes from intravascular ultrasound (IVUS), an imaging method that measures the arterial wall and plaque from inside a coronary artery. The trials typically report percent atheroma volume, the proportion of the measured vessel volume occupied by plaque. A decrease in that measurement is evidence of a smaller average plaque burden within the imaged segment. It does not mean that an artery’s narrowing improved by the same number of percentage points or that a blockage disappeared.
In the randomized GLAGOV trial, published in JAMA in 2016, 968 patients with coronary disease received either evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, or placebo in addition to background statin therapy. Of these, 846 had evaluable ultrasound scans at baseline and follow-up. Over approximately 76 weeks of treatment, average time-weighted LDL-C was 36.6 mg/dL with evolocumab and 93.0 mg/dL with placebo.
Mean percent atheroma volume fell by 0.95 percentage points with evolocumab and rose by 0.05 percentage points with placebo. Regression was documented in 64.3% versus 47.3% of patients, respectively. That finding is often summarized as evidence that lowering LDL-C can reverse plaque, but the imaging changes were generally small and varied between individuals.
A trial after heart attack found changes in plaque size and composition
The PACMAN-AMI randomized trial, published in JAMA in 2022, studied 300 patients after an acute myocardial infarction (heart attack). Participants received high-intensity statin therapy and were assigned to injections of alirocumab, another PCSK9 inhibitor, or placebo. Investigators measured plaque in coronary arteries other than the one responsible for the heart attack, using three complementary imaging methods.
After 52 weeks, 265 participants had evaluable serial IVUS scans. Mean percent atheroma volume declined by 2.13 percentage points in the alirocumab group and by 0.92 percentage points in the placebo group, an adjusted between-group difference of 1.21 percentage points. At 52 weeks, mean LDL-C was 23.6 mg/dL with alirocumab and 74.4 mg/dL with placebo among participants with follow-up imaging.
Two other imaging findings add context. Alirocumab produced a larger reduction in a measure of the lipid-rich plaque core and a larger increase in the minimum thickness of the plaque’s fibrous covering. The average fibrous-cap increase was 62.67 micrometers versus 33.19 micrometers. These changes suggest that LDL lowering can alter plaque structure as well as volume, although imaging measurements cannot establish how any particular plaque will behave in the future.
Evidence that statins themselves can shrink plaque predates PCSK9 inhibitors. In the 2006 ASTEROID study, 349 patients had evaluable coronary imaging after two years of rosuvastatin 40 mg daily. Average LDL-C fell from 130.4 to 60.8 mg/dL, and mean percent atheroma volume declined by 0.98 percentage points. ASTEROID was a single-arm study without a randomized control group, which limits causal interpretation of that particular before-and-after comparison.
A 2026 trial found greater plaque regression with more intensive cholesterol treatment
A prespecified secondary analysis of the FLOWPROMOTE randomized clinical trial, published online October 30, 2026, in JAMA Cardiology, assessed 104 adults with newly diagnosed stable coronary artery disease who had not previously taken statins. Participants were randomized equally to atorvastatin 40 mg daily or rosuvastatin 40 mg plus ezetimibe 10 mg daily. Coronary computed tomography angiography (CTA) was performed at baseline, nine months, and 18 months to measure plaque across the coronary arteries.
At 18 months, mean LDL-C had fallen from 127.4 to 42.5 mg/dL in the combination-therapy group and from 119.7 to 69.5 mg/dL in the atorvastatin group. Total coronary plaque volume declined by 21.1% with combination therapy versus 13.6% with atorvastatin alone. Noncalcified plaque volume fell by 28.2% and 20.0%, respectively, while calcified plaque volume increased similarly in both groups.
Some regression in total plaque volume was recorded in 47 of 52 participants (90%) receiving combination therapy and 38 of 51 (75%) receiving atorvastatin alone. These percentages describe imaging changes, not the proportion of an artery’s narrowing that disappeared. The analysis involved a small, selected population with established coronary disease and measured prespecified secondary imaging outcomes rather than heart attacks or deaths. Because the regimens differed in both statin and use of ezetimibe, the trial also cannot isolate the effect of adding ezetimibe. The findings strengthen evidence for partial plaque regression with intensive LDL-C lowering, but do not show that the more intensive regimen prevents more cardiovascular events in this population.
Plaque regression and plaque stabilization are not the same outcome
Atherosclerotic plaque contains more than cholesterol. Lipid, inflammatory cells, fibrous tissue, and calcium can be present in different proportions. A treatment might reduce the overall plaque volume, reduce lipid content, increase fibrous-cap thickness, or change the extent and density of calcification. Those are related but distinct outcomes.
In particular, a rising coronary artery calcium score after starting a statin does not automatically mean treatment has failed. Statins can increase the calcified component or density of plaque even as other high-risk features improve. Calcium scoring is useful for selected risk-assessment decisions, but it is not a straightforward before-and-after measure of whether a statin has successfully removed soft plaque. The distinction matters when interpreting imaging results alongside a patient’s lipid panel and non-HDL cholesterol.
Severe narrowing may also remain even when plaque biology improves. Symptomatic or high-risk obstructions can require assessment and treatment for reasons that cannot be resolved by a favorable laboratory cholesterol result alone. LDL-lowering drugs should therefore not be described as a replacement for indicated evaluation of chest pain or established obstructive coronary disease.
Preventing heart attacks has stronger clinical evidence than clearing arteries
Serial-imaging studies establish that plaque measurements can improve. They do not, by themselves, prove that the observed imaging change prevented a heart attack. Large cardiovascular outcome trials answer a different and more important clinical question: whether treatment reduces events that matter to patients.
In the FOURIER randomized trial, published in The New England Journal of Medicine in 2017, 27,564 patients with established atherosclerotic cardiovascular disease already receiving statins were assigned to evolocumab or placebo. Over a median 2.2 years, the primary composite outcome of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, or coronary revascularization occurred in 9.8% of evolocumab-treated participants versus 11.3% of placebo-treated participants. That was a 15% relative reduction in the composite event hazard. The trial did not demonstrate a reduction in cardiovascular death alone during that follow-up.
FOURIER was not a test of whether the same participants’ coronary plaques disappeared. Read alongside the imaging trials, it supports the clinical case for appropriately selected LDL-lowering therapy without equating an ultrasound measurement with an individual patient’s risk. Other markers, including apolipoprotein B and LDL-C, can help refine assessment of atherogenic lipoprotein exposure.
The 2026 guidelines set LDL goals according to cardiovascular risk
The 2026 US dyslipidemia guideline emphasizes reducing cumulative exposure to atherogenic cholesterol particles and matching treatment intensity to a person’s risk. For patients with established atherosclerotic cardiovascular disease at very high risk of another event, it recommends an LDL-C goal below 55 mg/dL. Other risk groups have different goals. These values are treatment targets in specified clinical settings, not a promise that reaching a threshold will dissolve existing plaque.
Statins remain a foundation of evidence-based risk reduction, with additional LDL-lowering medications considered when indicated. Dietary changes, physical activity, smoking cessation, blood pressure control, and diabetes management remain relevant even when cholesterol medications are prescribed. The amount of lowering required depends on the overall clinical picture, not on a single cholesterol measurement or the appearance of an isolated plaque.
People without known cardiovascular disease should not infer from these imaging trials that they need injectable cholesterol drugs. The participants generally had documented coronary disease and were frequently already receiving intensive treatment. Risk assessment and medication choices should be discussed with a clinician, especially if symptoms, previous cardiovascular events, familial high cholesterol, or elevated lipoprotein(a) are present.
What the evidence cannot yet tell an individual patient
These trials have important limits. GLAGOV and PACMAN-AMI enrolled selected patients with established coronary disease who underwent invasive arterial imaging, rather than a representative sample of otherwise healthy adults. Some randomized participants did not have usable follow-up scans. The imaging results were measured over roughly one to two years and cannot predict whether every lesion in a person’s coronary arteries will regress or remain stable over decades.
The studies also used surrogate imaging endpoints. Changes in percent atheroma volume, lipid-core burden, and fibrous-cap thickness cannot be translated directly into an individual’s probability of avoiding a heart attack. PACMAN-AMI was a relatively small trial, with support from companies involved in the treatment and imaging technology. GLAGOV and FOURIER also evaluated a commercially developed PCSK9 inhibitor; interpreting the results requires attention to their different designs and endpoints.
The PACMAN-AMI authors were explicit about that gap: “Further research is needed to understand whether alirocumab improves clinical outcomes in this population.” Their caution concerned patients treated soon after myocardial infarction, while separate outcomes trials have established cardiovascular event reductions in broader high-risk populations. The defensible answer to the question in the headline is therefore narrow but meaningful: substantial LDL-C lowering can produce modest coronary plaque regression and favorable changes in plaque composition in some patients. Its established clinical purpose is to lower future cardiovascular risk, not to guarantee that an existing blockage disappears.
References
- Nicholls SJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316:2373–2384. DOI: 10.1001/jama.2016.16951.
- Raber L, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771–1781. DOI: 10.1001/jama.2022.5218.
- Mortensen MB, et al. Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial. JAMA Cardiology. Published online October 30, 2026. DOI: 10.1001/jamacardio.2026.4788.
- Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–1722. DOI: 10.1056/NEJMoa1615664.
- American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2026 Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. DOI: 10.1161/CIR.0000000000001423.